| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vivo |
A2-Iso5-2DC18 transfects central antigen-presenting cells (APCs) in the A14 /Cre mRNA mouse model by loading it with either mLuc or Cre-recombinase mRNA LNPs (mCre) at doses of 0.1 mg/kg and 0.5 mg/kg, subcutaneously, once every week for two weeks[1]. In the B16F10 mouse melanoma model, A2-Iso5-2DC18 loaded with OVA mRNA (mOVA) vaccination (15 μg mOVA per animal; sc; twice dosage, once every 5 d) elicits a robust IFN-ɤ production concurrently with a significantly high antigen-specific cytotoxic T lymphocyte (CTL) response[1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: A14/Cre mRNA mouse model (female B6 mice)[1]
Doses: Loaded with Cre-recombinase mRNA LNPs (mCre ); 0.1 mg/kg and 0.5 mg/kg Route of Administration: subcutaneous (sc) injection; 3 weeks Experimental Results: Induced protein expression in the local injection site and the draining lymph nodes and transfected central antigen presenting cells (APCs) including macrophages/monocytes (CD11b+) and dendritic cells (CD11c+) in mice. Animal/Disease Models: Ovalbumin (OVA)-expressing B16F10 mouse melanoma model[1] Doses: Loaded with OVA mRNA (mOVA) vaccine; 15 μg mOVA per mouse Route of Administration: subcutaneous (sc) injection; once per week for the first two weeks; 3 weeks continuous observation Experimental Results: Dramatically diminished tumor volume of B16-OVA melanoma and improved overall survival in mice. Increased the number of systemic and tumor-infiltrating antigen-specific T cells dramatically (20–30-fold). |
| References |
[1]. Miao L, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019 Oct;37(10):1174-1185.
|
| Molecular Formula |
C47H87N3O2
|
|---|---|
| Molecular Weight |
726.21
|
| Exact Mass |
725.679
|
| CAS # |
2412492-07-8
|
| PubChem CID |
146461367
|
| Appearance |
Light yellow to yellow liquid（Density：0.95±0.1 g/cm3）
|
| LogP |
16.6
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
37
|
| Heavy Atom Count |
52
|
| Complexity |
868
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC
|
| InChi Key |
WMYPEEPUVOTFJU-WRBBJXAJSA-N
|
| InChi Code |
InChI=1S/C47H87N3O2/c1-4-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38-47(39-34-32-30-28-26-24-22-20-18-16-14-12-10-8-5-2)44-48-45(46(51)52-6-3)50(47)43-37-42-49-40-35-36-41-49/h19-22,44-45H,4-18,23-43H2,1-3H3/b21-19-,22-20-
|
| Chemical Name |
ethyl 5,5-bis[(Z)-heptadec-8-enyl]-1-(3-pyrrolidin-1-ylpropyl)-2H-imidazole-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (137.70 mM）
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.44 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3770 mL | 6.8851 mL | 13.7701 mL | |
| 5 mM | 0.2754 mL | 1.3770 mL | 2.7540 mL | |
| 10 mM | 0.1377 mL | 0.6885 mL | 1.3770 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
